{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:56:11Z","timestamp":1792457771877,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.blre.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T21:45:19Z","timestamp":1554327919000},"page":"100572","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kouides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Dow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Berntorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.04.001_bb0005","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2516.2006.01393.x","article-title":"The 80th anniversary of von Willebrand's disease: history, management and research","volume":"12","author":"Federici","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0015","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand's disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.blre.2019.04.001_bb0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0025","first-page":"262","article-title":"Towards personalised therapy for von Willebrand disease: a future role for recombinant products","volume":"14","author":"Favaloro","year":"2016","journal-title":"Blood Transfus"},{"key":"10.1016\/j.blre.2019.04.001_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620715587879","article-title":"Current controversies in the diagnosis and management of von Willebrand disease","volume":"6","author":"Neff","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2019.04.001_bb0035","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2003-06-2072","article-title":"Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study","volume":"103","author":"Federici","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0040","author":"American Society of Hematology Working Group"},{"key":"10.1016\/j.blre.2019.04.001_bb0045","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1182\/blood-2007-08-109231","article-title":"Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD","volume":"111","author":"Castaman","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0050","series-title":"Veyvondi. 650 IU, 1300 IU (powder and solvent for solution for injection). Summary of Product Characteristics","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.blre.2019.04.001_bb0055","series-title":"Vonvendi\u00ae [von Willebrand factor (recombinant)]. Lyophilized powder for solution for intravenous injection. Full prescribing information","author":"US Food and Drug Administration","year":"2018"},{"key":"10.1016\/j.blre.2019.04.001_bb0060","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"Gill","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0065","first-page":"94","article-title":"Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman","year":"2003","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.04.001_bb0070","first-page":"S32","article-title":"Development of a plasma- and albumin-free recombinant von Willebrand factor","volume":"29","author":"Turecek","year":"2009","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.blre.2019.04.001_bb0075","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1055\/s-2006-949668","article-title":"Comparative analysis and classification of von Willebrand factor\/factor VIII concentrates: impact on treatment of patients with von Willebrand disease","volume":"32","author":"Budde","year":"2006","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MBC.0b013e3283254570","article-title":"Von Willebrand factor\/factor VIII concentrates in the treatment of von Willebrand disease","volume":"20","author":"Batlle","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2019.04.001_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/jth.13551","article-title":"Von Willebrand factor and angiogenesis: basic and applied issues","volume":"15","author":"Randi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ejh.12514","article-title":"Interaction between VWF and FVIII in treating VWD","volume":"95","author":"Miesbach","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.04.001_bb0095","series-title":"Alphanate\u00ae (antihemophilic factor\/von Willebrand factor complex [human]). Sterile, lyophilized powder for injection. Full prescribing information","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.blre.2019.04.001_bb0100","series-title":"Alphanate\u00ae (powder for injection). Summary of product characteristics","author":"Electronic Medicines Compendium","year":"2016"},{"key":"10.1016\/j.blre.2019.04.001_bb0105","series-title":"Human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF) complex, powder for injection. Consumer Medicine Information","author":"Biostate\u00ae","year":"2017"},{"key":"10.1016\/j.blre.2019.04.001_bb0110","series-title":"Fanhdi\u00ae. Human coagulation factor VIII, Ph. Eur. (25, 50, 100 IU\/ml powder and solvent for solution for injection). Summary of product characteristics","author":"Electronic Medicines Compendium","year":"2018"},{"key":"10.1016\/j.blre.2019.04.001_bb0115","series-title":"Haemate-P\u00ae (1000 IU powder and solvent for solution for injection or infusion). Summary of product characteristics","author":"Electronic Medicines Compendium","year":"2018"},{"key":"10.1016\/j.blre.2019.04.001_bb0120","series-title":"(antihemophilic factor\/von Willebrand factor complex [human]) lyophilized powder for reconstitution for intravenous use only. Full prescribing information","author":"Humate-P\u00ae","year":"2014"},{"key":"10.1016\/j.blre.2019.04.001_bb0125","series-title":"Voncento\u00ae (1000 IU FVIII \/ 2400 IU VWF [10 ml solvent] powder and solvent for solution for injection\/infusion). Summary of product characteristics","author":"Electronic Medicines Compendium","year":"2018"},{"key":"10.1016\/j.blre.2019.04.001_bb0130","series-title":"Wilate\u00ae, von Willebrand factor\/coagulation factor VIII complex (human). Lyophilized powder for solution for intravenous injection. Full prescribing information","author":"US Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.blre.2019.04.001_bb0135","series-title":"Wilate\u00ae (powder and solvent for solution for injection). Summary of product characteristics","author":"Electronic Medicines Compendium","year":"2014"},{"key":"10.1016\/j.blre.2019.04.001_bb0140","series-title":"Willfact\/Willfactin\u00ae (1000 IU powder and solvent for solution for injection). Summary of product characteristics","author":"Electronic Medicines Compendium","year":"2016"},{"key":"10.1016\/j.blre.2019.04.001_bb0150","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0155","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hae.12496","article-title":"Safety and efficacy of a von Willebrand factor\/factor VIII concentrate (Wilate\u00ae): a single centre experience","volume":"20","author":"Batty","year":"2014","journal-title":"Haemophilia"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2019.04.001_bb0160","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2516.2007.01570.x","article-title":"Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results","volume":"13","author":"Bello","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0165","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease - efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0170","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1538-7836.2007.02562.x","article-title":"Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients","volume":"5","author":"Borel-Derlon","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0175","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1365-2516.2010.02206.x","article-title":"Clinical efficacy and safety of the factor VIII\/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study","volume":"16","author":"Dunkley","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0180","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2516.2009.02088.x","article-title":"Efficacy and safety of highly purified, doubly virus-inactivated VWF\/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score","volume":"16","author":"Federici","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1046\/j.1365-2516.2002.00688.x","article-title":"Clinical efficacy of highly purified, doubly virus-inactivated factor VIII\/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study","volume":"8","author":"Federici","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0190","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3324\/haematol.11124","article-title":"Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients","volume":"92","author":"Federici","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.04.001_bb0195","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2516.2011.02534.x","article-title":"von Willebrand factor\/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease","volume":"17","author":"Gill","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0200","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","article-title":"Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods","volume":"3","author":"Goudemand","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0205","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1365-2516.2008.01784.x","article-title":"Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII\/VWF concentrate","volume":"14","author":"Hernandez-Navarro","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0210","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2516.2010.02445.x","article-title":"The clinical efficacy and safety of the FVIII\/VWF concentrate, BIOSTATE\u00ae, in children with von Willebrand disorder: a multi-centre retrospective review","volume":"17","author":"Howman","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0215","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/hae.12497","article-title":"Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience","volume":"21","author":"Khair","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0220","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"von Willebrand factor\/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0225","doi-asserted-by":"crossref","unstructured":"Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII\/von Willebrand factor concentrate, Haemate-P\/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224\u201330.","DOI":"10.1055\/s-0037-1612977"},{"key":"10.1016\/j.blre.2019.04.001_bb0230","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MBC.0000000000000568","article-title":"Pharmacokinetics, efficacy, and safety of a plasma-derived VWF\/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)","volume":"28","author":"Lissitchkov","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2019.04.001_bb0235","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0240","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2516.2007.01616.x","article-title":"Efficacy of factor VIII\/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease","volume":"14","author":"Rivard","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0245","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2516.2006.01430.x","article-title":"Efficacy and safety of a high purity, double virus inactivated factor VIII\/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures","volume":"13","author":"Shortt","year":"2007","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0250","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hae.13106","article-title":"Efficacy and safety of a VWF\/FVIII concentrate (wilate\u00ae) in inherited von Willebrand disease patients undergoing surgical procedures","volume":"23","author":"Srivastava","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0255","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1160\/TH10-10-0631","article-title":"Efficacy and safety of a new generation von Willebrand factor\/factor VIII concentrate (Wilate\u00ae) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery","volume":"105","author":"Windyga","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0260","author":"National Hemophilia Foundation"},{"key":"10.1016\/j.blre.2019.04.001_bb0265","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood.V30.3.375.375","article-title":"Correction of the hemostatic defects in Von Willebrand's disease","volume":"30","author":"Perkins","year":"1967","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0270","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1537-2995.2012.03907.x","article-title":"Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening","volume":"53","author":"Soucie","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.04.001_bb0275","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","article-title":"Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis","volume":"25","author":"Stockschlaeder","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2019.04.001_bb0280","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1182\/blood.V83.10.3018.3018","article-title":"Proteolysis of von Willebrand factor in therapeutic plasma concentrates","volume":"83","author":"Mannuccio","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0285","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/17474086.2016.1214070","article-title":"Von Willebrand factor (Vonvendi\u00ae): the first recombinant product licensed for the treatment of von Willebrand disease","volume":"9","author":"Franchini","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2019.04.001_bb0290","doi-asserted-by":"crossref","first-page":"667","DOI":"10.3324\/haematol.2012.077263","article-title":"Principles of care for the diagnosis and treatment of von Willebrand disease","volume":"98","author":"Castaman","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.04.001_bb0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.rmed.2017.01.008","article-title":"Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: study of efficacy and safety","volume":"124","author":"Mansur","year":"2017","journal-title":"Respir Med"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.04.001_bb0300","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/01.mbc.0000167658.85143.49","article-title":"Management of von Willebrand disease with factor VIII\/von Willebrand factor concentrates: results from current studies and surveys","volume":"16","author":"Federici","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2019.04.001_bb0305","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1351-8216.2003.00816.x","article-title":"Successful treatment of urgent bleeding in von Willebrand disease with factor VIII\/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy","volume":"9","author":"Gill","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0310","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2013-01-479527","article-title":"Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial","volume":"122","author":"Mannucci","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0315","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0092-8674(00)80983-6","article-title":"Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor","volume":"84","author":"Savage","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.blre.2019.04.001_bb0320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jth.14313","article-title":"Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery","volume":"17","author":"Peyvandi","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0325","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/trf.14241","article-title":"Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data","volume":"57","author":"Kouides","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.blre.2019.04.001_bb0330","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/hae.13165","article-title":"Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease","volume":"23","author":"Mannucci","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.04.001_bb0335","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH08-07-0449","article-title":"A better approach to monitoring of therapy in von Willebrand disease?","volume":"100","author":"Favaloro","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0340","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2016-03-703231","article-title":"VWD diagnosis: improved","volume":"127","author":"James","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0345","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2015-11-664680","article-title":"Rapid discrimination of the phenotypic variants of von Willebrand disease","volume":"127","author":"Roberts","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.04.001_bb0350","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1538-7836.2008.02845.x","article-title":"A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry","volume":"6","author":"Chen","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0355","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/09537104.2017.1420153","article-title":"Sensitive and specific assessment of recombinant von Willebrand factor in platelet function analyzer","volume":"30","author":"Pekrul","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.blre.2019.04.001_bb0360","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/bjh.13064","article-title":"The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology","volume":"167","author":"Laffan","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.04.001_bb0365","author":"The International Society on Thrombosis and Haemostasis Press Release"},{"key":"10.1016\/j.blre.2019.04.001_bb0370","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand's disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.04.001_bb0375","first-page":"880","article-title":"Treatment of gastrointestinal bleeding episodes with recombinant von Willebrand factor (rVWF) in patients with severe von Willebrand disease (VWD): sub-analysis from pivotal phase III on-demand study","volume":"1","author":"Leebeek","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2019.04.001_bb0380","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/00000441-196711000-00002","article-title":"Telangiectasia: its relationship to the Minot-von Willebrand syndrome","volume":"254","author":"Quick","year":"1967","journal-title":"Am J Med Sci"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18300158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18300158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:21:59Z","timestamp":1759436519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18300158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":75,"alternative-id":["S0268960X18300158"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.04.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of replacement therapy for von Willebrand disease: From plasma fraction to recombinant von Willebrand factor","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Shire International GmbH and the Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100572"}}